JP2023540022A5 - - Google Patents

Info

Publication number
JP2023540022A5
JP2023540022A5 JP2023513271A JP2023513271A JP2023540022A5 JP 2023540022 A5 JP2023540022 A5 JP 2023540022A5 JP 2023513271 A JP2023513271 A JP 2023513271A JP 2023513271 A JP2023513271 A JP 2023513271A JP 2023540022 A5 JP2023540022 A5 JP 2023540022A5
Authority
JP
Japan
Application number
JP2023513271A
Other languages
Japanese (ja)
Other versions
JP2023540022A (ja
JPWO2022043315A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/073369 external-priority patent/WO2022043315A1/en
Publication of JP2023540022A publication Critical patent/JP2023540022A/ja
Publication of JP2023540022A5 publication Critical patent/JP2023540022A5/ja
Publication of JPWO2022043315A5 publication Critical patent/JPWO2022043315A5/ja
Pending legal-status Critical Current

Links

JP2023513271A 2020-08-24 2021-08-24 チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにCD44v6を認識するCAR発現細胞 Pending JP2023540022A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20192399.2 2020-08-24
EP20192399 2020-08-24
EP20205696.6 2020-11-04
EP20205696 2020-11-04
PCT/EP2021/073369 WO2022043315A1 (en) 2020-08-24 2021-08-24 A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6

Publications (3)

Publication Number Publication Date
JP2023540022A JP2023540022A (ja) 2023-09-21
JP2023540022A5 true JP2023540022A5 (https=) 2024-09-02
JPWO2022043315A5 JPWO2022043315A5 (https=) 2024-09-02

Family

ID=77710751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513271A Pending JP2023540022A (ja) 2020-08-24 2021-08-24 チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにCD44v6を認識するCAR発現細胞

Country Status (5)

Country Link
US (1) US20240009310A1 (https=)
EP (1) EP4199959A1 (https=)
JP (1) JP2023540022A (https=)
AU (1) AU2021334107A1 (https=)
WO (1) WO2022043315A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7849891B2 (ja) * 2020-08-24 2026-04-22 シャリテ-ウニベルジテーツメディツィン ベルリン Ceaを認識するキメラ抗原受容体(car)発現細胞
WO2024093147A1 (zh) * 2022-10-31 2024-05-10 南京元迈细胞生物科技有限公司 一种特异性结合CD44的v5外显子的抗体及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6489458B2 (en) 1997-03-11 2002-12-03 Regents Of The University Of Minnesota DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
EP1079688A1 (en) 1998-05-26 2001-03-07 Innogenetics N.V. Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP2160461B1 (en) 2007-07-04 2012-08-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Hyperactive variants of the transposase protein of the transposon system sleeping beauty
CA2984624A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
WO2017040945A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
AU2018231190B2 (en) * 2017-03-08 2023-05-25 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
WO2018195339A1 (en) * 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
US11701405B2 (en) * 2018-01-26 2023-07-18 City Of Hope Chimeric antigen receptors and methods for reducing toxicity
EP3784256A4 (en) * 2018-04-27 2022-06-29 Baylor College of Medicine Car t cells with one or more interleukins

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
JP2023540022A5 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)